Association of the inflammatory marker suPAR with chronic pruritus of unknown origin – data from the SOMA.PRU study - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Link Between suPAR Inflammatory Marker and Chronic Pruritus of Unidentified Cause: Insights from the SOMA.PRU Study

  • By

  • Stefan M. Kahnert

  • Lara Jürgens

  • Leonie Dreher

  • Christian Schmidt-Lauber

  • Ansgar Koechel

  • Gina L. Frank

  • Tobias B. Huber

  • Meike Shedden-Mora

  • Sonja Ständer

  • Markus Ramm

  • Gudrun Schneider

  • Rupert Conrad

  • June 16, 2026

Share

  • 1

    Chronic pruritus of unknown origin (CPUO) affects 6-15% of pruritus patients and significantly impacts quality of life.

  • 2

    The study found that patients with CPUO had the highest serum levels of suPAR compared to chronic atopic dermatitis (cAD) and controls.

  • 3

    Higher baseline suPAR levels in CPUO patients correlated with increased pruritus intensity at the six-month follow-up.

  • 4

    suPAR may serve as a biomarker for systemic chronic inflammation associated with the clinical course of CPUO.

  • 5

    The findings suggest that chronic systemic inflammation plays a significant role in the persistence of CPUO.

Original Source(s)

Association of the inflammatory marker suPAR with chronic pruritus of unknown origin – data from the SOMA.PRU study

  • by Stefan M. Kahnert, Lara Jürgens, Leonie Dreher, Christian Schmidt-Lauber, Ansgar Koechel, Gina L. Frank, Tobias B. Huber, Meike Shedden-Mora, Sonja Ständer, Markus Ramm, Gudrun Schneider, Rupert Conrad

  • June 16, 2026

Related Content

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.

Correction: Ivarmacitinib in atopic dermatitis presenting with prurigo nodularis-like lesions and alopecia areata: a case report

The Role of Inflammatory Biomarkers in Disease Severity and Treatment Response across Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa—A Narrative Review